The proteomic landscape of triple-negative breast cancer.

Triple-negative breast cancer is a heterogeneous disease characterized by poor clinical outcomes and a shortage of targeted treatment options. To discover molecular features of triple-negative breast cancer, we performed quantitative proteomics analysis of twenty human-derived breast cell lines and four primary breast tumors to a depth of more than 12,000 distinct proteins. We used this data to identify breast cancer subtypes at the protein level and demonstrate the precise quantification of biomarkers, signaling proteins, and biological pathways by mass spectrometry. We integrated proteomics data with exome sequence resources to identify genomic aberrations that affect protein expression. We performed a high-throughput drug screen to identify protein markers of drug sensitivity and understand the mechanisms of drug resistance. The genome and proteome provide complementary information that, when combined, yield a powerful engine for therapeutic discovery. This resource is available to the cancer research community to catalyze further analysis and investigation.

[1]  C. Hudis,et al.  Triple-negative breast cancer: an unmet medical need. , 2011, The oncologist.

[2]  M. Mann,et al.  Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips , 2007, Nature Protocols.

[3]  M. Eck,et al.  The FERM domain: organizing the structure and function of FAK , 2010, Nature Reviews Molecular Cell Biology.

[4]  Z. Gatalica,et al.  Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies. , 2011, Oncology letters.

[5]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[6]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[7]  J. Baselga,et al.  Impact of Genomics on Personalized Cancer Medicine , 2012, Clinical Cancer Research.

[8]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[9]  Adam A. Margolin,et al.  Assessing the clinical utility of cancer genomic and proteomic data across tumor types , 2014, Nature Biotechnology.

[10]  Z. Hall.  Cancer , 1906, The Hospital.

[11]  S. Lemon,et al.  p21-activated Kinase 1 Is Activated through the Mammalian Target of Rapamycin/p70 S6 Kinase Pathway and Regulates the Replication of Hepatitis C Virus in Human Hepatoma Cells* , 2007, Journal of Biological Chemistry.

[12]  L. Martiny,et al.  CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest , 2012, British journal of pharmacology.

[13]  E. Brown,et al.  Integrin-associated protein (CD47) and its ligands. , 2001, Trends in cell biology.

[14]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[15]  Laura M. Heiser,et al.  A community effort to assess and improve drug sensitivity prediction algorithms , 2014, Nature Biotechnology.

[16]  S. Gygi,et al.  Correlation between Protein and mRNA Abundance in Yeast , 1999, Molecular and Cellular Biology.

[17]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[18]  M. Hung,et al.  The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines , 2010, Breast cancer : basic and clinical research.

[19]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[20]  Matthias Mann,et al.  Proteomic portrait of human breast cancer progression identifies novel prognostic markers. , 2012, Cancer research.

[21]  Jung-Sik Kim,et al.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors , 2009, EMBO molecular medicine.

[22]  Pei Wang,et al.  Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins , 2013, Nature Methods.

[23]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[24]  Genee Y. Lee,et al.  The morphologies of breast cancer cell lines in three‐dimensional assays correlate with their profiles of gene expression , 2007, Molecular oncology.

[25]  Gary D Bader,et al.  A draft map of the human proteome , 2014, Nature.

[26]  Andreas Sommer,et al.  NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression , 2004 .

[27]  B. Kuster,et al.  Mass-spectrometry-based draft of the human proteome , 2014, Nature.

[28]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[29]  M. Smyth,et al.  Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis , 2010, Proceedings of the National Academy of Sciences.

[30]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[31]  M. Untch,et al.  Current and future role of neoadjuvant therapy for breast cancer. , 2014, Breast.

[32]  M. Selbach,et al.  Global quantification of mammalian gene expression control , 2011, Nature.

[33]  Nci Dream Community.  A community effort to assess and improve drug sensitivity prediction algorithms , 2014 .

[34]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[35]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[36]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[37]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[38]  E. Lundberg,et al.  Towards a knowledge-based Human Protein Atlas , 2010, Nature Biotechnology.

[39]  B. Manning.  Balancing Akt with S6K , 2004, The Journal of cell biology.

[40]  J. Ellenberg,et al.  The quantitative proteome of a human cell line , 2011, Molecular systems biology.

[41]  H Zimmermann,et al.  5'-Nucleotidase: molecular structure and functional aspects. , 1992, The Biochemical journal.

[42]  M. Mann,et al.  Comparative Proteomic Analysis of Eleven Common Cell Lines Reveals Ubiquitous but Varying Expression of Most Proteins* , 2012, Molecular & Cellular Proteomics.

[43]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[44]  Mathias Wilhelm,et al.  Global proteome analysis of the NCI-60 cell line panel. , 2013, Cell reports.

[45]  Jeffrey R. Whiteaker,et al.  Proteogenomic characterization of human colon and rectal cancer , 2014, Nature.

[46]  L. Yin,et al.  RNAi‐mediated CD73 suppression induces apoptosis and cell‐cycle arrest in human breast cancer cells , 2010, Cancer science.

[47]  G. S. Johnson,et al.  An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.

[48]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[49]  Kathleen A Cronin,et al.  US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. , 2014, Journal of the National Cancer Institute.

[50]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[51]  H. Sakurai,et al.  IκB Kinases Phosphorylate NF-κB p65 Subunit on Serine 536 in the Transactivation Domain* , 1999, The Journal of Biological Chemistry.

[52]  M. Karin,et al.  Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression , 2004 .

[53]  H. Sakurai,et al.  IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. , 1999, The Journal of biological chemistry.

[54]  Mark Gerstein,et al.  The human proteome – a scientific opportunity for transforming diagnostics, therapeutics, and healthcare , 2012, Clinical Proteomics.

[55]  H. Pehamberger,et al.  NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. , 2004, The Journal of clinical investigation.

[56]  Luis Serrano,et al.  Correlation of mRNA and protein in complex biological samples , 2009, FEBS letters.

[57]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[58]  Martin Kircher,et al.  Deep proteome and transcriptome mapping of a human cancer cell line , 2011, Molecular systems biology.

[59]  L. Hood,et al.  Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine , 2012, Journal of internal medicine.

[60]  J. Ciezki,et al.  PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells , 2013, PloS one.

[61]  Neil O. Carragher,et al.  The role of focal-adhesion kinase in cancer — a new therapeutic opportunity , 2005, Nature Reviews Cancer.

[62]  Hiroyuki Oshiumi,et al.  DDX60, a DEXD/H Box Helicase, Is a Novel Antiviral Factor Promoting RIG-I-Like Receptor-Mediated Signaling , 2011, Molecular and Cellular Biology.

[63]  M. Karin,et al.  Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. , 2004, Cancer cell.

[64]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[65]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[66]  Yigong Shi,et al.  PPM1A Functions as a Smad Phosphatase to Terminate TGFβ Signaling , 2016, Cell.